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Introduction: Dolutegravir (DTG) 50 mg once daily was superior to darunavir/ritonavir (DRV/r) 800 mg/100 mg once daily
through Week 48, with 90% vs. 83% of participants achieving HIV RNA 50 c/mL (p0.025) [1]. We present data through
Week 96.
Materials and Methods: FLAMINGO is a multicentre, randomized, open-label, Phase IIIb non-inferiority study, in which HIV-1-
positive ART-naı¨ve adults with HIV-1 RNA]1000 c/mL and no evidence of viral resistance were randomized 1:1 to receive DTG
or DRV/r, with investigator-selected backbone NRTIs (TDF/FTC or ABC/3TC). Participants were stratified by screening HIV-1 RNA
(5100K c/mL) and NRTI backbone.
Results: A total of 484 adults were randomized and treated; 25% had baseline HIV RNA 100K c/mL. At Week 96, the proportion
of participants with HIV RNA 50 c/mL was 80% in the DTG arm vs. 68% in the DRV/r arm (adjusted difference 12.4%; 95% CI 4.7,
20.2%; p0.002). Secondary analyses supported primary results: per-protocol [(DTG 83% vs. DRV/r 70%), 95% CI 12.9 (5.3,
20.6)] and treatment-related discontinuation  failure [(98% vs. 95%), 95% CI 3.2 (0.3, 6.7)]. Overall virologic non-response
(DTG 8%; DRV/r 12%) and non-response due to other reasons (DTG 12%; DRV/r 21%) occurred less frequently on DTG. As at
Week 48, the difference between arms was most pronounced in participants with high baseline viral load (82% vs. 52% response
through Week 96) and in the TDF/FTC stratum (79% vs. 64%); consistent responses were seen in the ABC/3TC stratum (82% vs.
75%). Six participants (DTG 2, none post-Week 48; DRV/r 4, two post-Week 48) experienced protocol-defined virologic failure
(PDVF; confirmed viral load 200 c/mL on or after Week 24); none had treatment-emergent resistance to study drugs. Most
frequent drug-related adverse events (AEs) were diarrhoea, nausea and headache, with diarrhoea significantly more common on
DRV/r (24%) than DTG (10%). Significantly more participants had Grade 2 fasting LDL toxicities on DRV/r (22%) vs. DTG (7%),
pB0.001; mean changes in creatinine for DTG (0.18 mg/dL) observed at Week 2 were stable through Week 96.
Conclusions: Once-daily DTG was superior to once-daily DRV/r in treatment-naı¨ve HIV-1-positive individuals, with no evidence of
emergent resistance to DTG in virologic failure and relatively similar safety profiles for DTG and DRV/r through 96 Weeks.
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